Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

Q07869 (PPARA_HUMAN) Homo sapiens (Human)

Peroxisome proliferator-activated receptor alpha UniProtKBInterProSTRINGInteractive Modelling

468 aa; Sequence (Fasta) ; (Isoform 2); 3 identical sequences: Homo sapiens: F1D8S4; Pongo abelii: H2P4S5; Gorilla gorilla gorilla: A0A2I2Z0P2

Available Structures

63 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Structural basis for iloprost as a dual PPARalpha/delta agonist Heteromer
Q86YN6;
196-468
IL2;
Assess
Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid Heteromer
Q15788;
199-468
ET1;
Assess
X-ray structure of human PPARalpha ligand binding domain-fenofibric acid-SRC1 coactivator peptide c… Heteromer
Q15788;
200-468
F5A;
Assess
X-ray structure of human PPARalpha ligand binding domain-clofibric acid-SRC1 coactivator peptide co… Heteromer
Q15788;
200-468
E0O;
Assess
the crystal structure of the human PPARaplpha ligand binding domain in complex with a a-hydroxyimin… Heteromer
Q15788;
199-467
MMB;
Assess
X-ray structure of human PPARalpha ligand binding domain-bezafibrate-SRC1 coactivator peptide co-cr… Heteromer
Q15788;
200-468
PEM;
Assess
Novel natural PPARalpha agonist with a unique binding mode Heteromer
Q15788;
200-468
SAU;
Assess
X-ray structure of human PPAR alpha ligand binding domain-lanifibranor-SRC1 coactivator peptide co-… Heteromer
Q15788;
200-468
Assess
Crystal structure of the human PPAR-alpha ligand-binding domain in complex with an antagonist GW647… Heteromer
Q9Y618;
200-468
471;
Assess
X-ray structure of human PPARalpha ligand binding domain-pemafibrate-SRC1 coactivator peptide co-cr… Heteromer
Q15788;
201-468
P7F;GOL;
Assess
X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA)-SRC1 coactivat… Heteromer
Q15788;
201-468
EPA;GOL;
Assess
X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-SRC1… Heteromer
Q15788;
202-468
PLM;GOL;
Assess
X-ray structure of human PPAR alpha ligand binding domain-elafibranor-SRC1 coactivator peptide co-c… Heteromer
Q15788;
202-468
GOL;MUO;
Assess
a crystal structure of PPAR alpha bound with SRC1 peptide and GW735 Heteromer
Q15788;
202-468
735;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW7647-SRC1 coactivator peptide co-crystal… Heteromer
Q15788;
202-468
2VN;
Assess
Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diab… Heteromer
Q15788;
202-468
RO7;
Assess
Design and biological evaluation of novel, balanced dual PPARa/g agonists Heteromer
Q15788;
202-468
CTM;
Assess
The 2.5 Angstrom resolution crystal structure of the human PPARalpha ligand binding domain bound wi… Heteromer
Q15788;
202-468
544;
Assess
Structure of PPARalpha-LBD/pemafibrate/SRC1 peptide Heteromer
Q15788;
202-467
P7F;
Assess
Ternary complex of hPPARalpha ligand binding domain, 17-oxoDHA and a SRC1 peptide Heteromer
Q15788;
204-468
4M5;
Assess
Human PPAR alpha ligand binding domain in complex with a synthetic agonist (compound A) Heteromer
Q9UBK2;
205-467
T02;
Assess
Human PPAR alpha ligand binding domain in complex with a synthetic agonist (compound B) Heteromer
Q9UBK2;
205-467
T06;
Assess
Crystal structure of peroxisome proliferator-activatedeceptor alpha (PPARalpha) complex with N-3-((…homo-2-mer196-468
NKS;
Assess
Crystal structure of peroxisome proliferator-activatedeceptor alpha (PPARalpha) complex with N-3-((…homo-2-mer196-468
7HA;
Assess
HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH APHM6 OBTAINED BY SOAKINGhomo-2-mer200-468
HW3;
Assess
HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH YN4pai OBTAINED BY SOAKINGhomo-2-mer200-468
HVX;
Assess
HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH APHM6 OBTAINED BY COCRYSTALLIZATIONhomo-2-mer200-468
HW3;
Assess
HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH TIPP703 OBTAINED BY SOAKINGhomo-2-mer200-468
S44;
Assess
CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN FROM HUMAN PPAR-ALPHA IN COMPLEX WITH THE AGONIST AZ…monomer199-468
NA;AZ2;CPQ;
Assess
X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA) co-crystals ob…monomer200-468
GOL;EPA;
Assess
X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin) co-c…monomer200-468
GOL;PLM;
Assess
X-ray structure of human PPARalpha ligand binding domain-tetradecylthioacetic acid (TTA) co-crystal…monomer200-468
GOL;T4T;
Assess
X-ray structure of human PPARalpha ligand binding domain-arachidonic acid co-crystals obtained by d…monomer200-468
GOL;ACD;
Assess
X-ray structure of human PPARalpha ligand binding domain-stearic acid co-crystals obtained by delip…monomer200-468
GOL;STE;
Assess
X-ray structure of human PPARalpha ligand binding domain-pemafibrate co-crystals obtained by delipi…monomer200-468
GOL;P7F;
Assess
X-ray structure of human PPARalpha ligand binding domain-tetradecylthioacetic acid (TTA) co-crystal…monomer200-468
GOL;T4T;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW7647 co-crystals obtained by delipidatio…monomer200-468
GOL;2VN;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW7647 co-crystals obtained by cross-seedi…monomer200-468
GOL;2VN;
Assess
X-ray structure of human PPARalpha ligand binding domain-pemafibrate co-crystals obtained by cross-…monomer200-468
GOL;P7F;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW7647 co-crystals obtained by soakingmonomer200-468
2VN;GOL;
Assess
X-ray structure of human PPARalpha ligand binding domain-ciprofibrate co-crystals obtained by delip…monomer200-468
GOL;C5F;
Assess
X-ray structure of human PPAR alpha ligand binding domain-seladelpar co-crystals obtained by cross-…monomer200-468
GOL;KKB;
Assess
X-ray structure of human PPARalpha ligand binding domain-saroglitazar co-crystals obtained by delip…monomer200-468
EWR;
Assess
X-ray structure of human PPARalpha ligand binding domain-fenofibric acid co-crystals obtained by de…monomer200-468
F5A;
Assess
Crystal Structure of PPARalpha ligand binding domain with BMS-631707monomer199-467
CPQ;REW;
Assess
X-ray structure of human PPARalpha ligand binding domain-saroglitazar co-crystals obtained by soaki…monomer200-468
EWR;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW9662-gemfibrozil co-crystals obtained by…monomer200-468
GW9;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW9662-clofibric acid co-crystals obtained…monomer200-468
GW9;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW9662-ciprofibrate co-crystals obtained b…monomer200-468
GW9;C5F;
Assess
X-ray structure of human PPARalpha ligand binding domain-GW9662-fenofibric acid co-crystals obtaine…monomer200-468
GW9;F5A;
Assess
X-ray structure of human PPARalpha ligand binding domain-5,8,11,14-eicosatetraynoic Acid (ETYA) co-…monomer201-468
GOL;ITY;
Assess
X-ray structure of human PPARalpha ligand binding domain-palmitic acid co-crystals obtained by deli…monomer202-468
GOL;PLM;
Assess
X-ray structure of human PPARalpha ligand binding domain-5,8,11,14-eicosatetraynoic acid (ETYA) co-…monomer202-468
GOL;ITY;
Assess
X-ray structure of human PPARalpha ligand binding domain-pemafibrate co-crystals obtained by soakingmonomer202-468
GOL;P7F;
Assess
X-ray structure of human PPARalpha ligand binding domain-oleic acid co-crystals obtained by delipid…monomer202-468
GOL;OLA;
Assess
Human PPAR alpha ligand binding domain in complex with a synthetic agonist APHM13monomer202-468
13M;
Assess
X-ray structure of human PPARalpha ligand binding domain-Wy14643 co-crystals obtained by co-crystal…monomer202-468
WY1;
Assess
Crystal structure of the complex PPARalpha/AL26-29monomer202-468
65W;
Assess
X-ray structure of human PPARalpha ligand binding domain-Wy14643 co-crystals obtained by soakingmonomer202-468
WY1;
Assess
Human PPAR alpha ligand binding domain in complex with a synthetic agonist TIPP703monomer202-468
S44;
Assess
X-ray structure of human PPARalpha ligand binding domain-Wy14643 co-crystals obtained by delipidati…monomer202-468
WY1;
Assess
Structural basis for GL479 a dual Peroxisome Proliferator-Activated Receptor alpha agonistmonomer204-467
Y1N;
Assess
Structure of PPARalpha in complex with WY14643monomer204-466
EDO;WY1;
Assess

7 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
3dzy.1.Bmonomer0.7099-468
ZN;64.96
Assess
7wnh.4.Amonomer0.59102-467
ZN;25.98
Assess
7wnh.2.Amonomer0.58101-464
ZN;25.98
Assess
4iqr.2.Amonomer0.53100-466
ZN;28.21
Assess
4iqr.2.Bmonomer0.52100-466
ZN;28.21
Assess
3dzu.1.Amonomer0.52102-460
ZN;34.81
Assess
4nqa.2.Amonomer0.51102-461
ZN;34.94
Assess

1 SWISS-MODEL model built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 23dzu.1.Bmonomer0.6999-173
ZN;77.92
Assess